Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Ferrannini

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
European Journal of Preventive Cardiology|February 24, 2021
Gender gap in risk factor control of coronary patients far from closing: results from the European Society of Cardiology EUROASPIRE V registryPieter Vynckier, Giulia Ferrannini, Lars Rydén, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|August 13, 2022
Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registry analysisGiulia Ferrannini, Lars H Lund, Lina Benson, et al.
Cardiovascular Diabetology|August 11, 2023
Empagliflozin improves insulin sensitivity in patients with recent acute coronary syndrome and newly detected dysglycaemia : Experiences from the randomized, controlled SOCOGAMI trialElena Fortin, Magnus Lundin, Linda Mellbin, et al.
The Lancet. Diabetes & Endocrinology|September 26, 2024
Dysglycaemia screening and its prognostic impact in patients with coronary artery disease: experiences from the EUROASPIRE IV and V cohort studiesGiulia Ferrannini, Jaakko Tuomilehto, Guy De Backer, et al.
Endocrine|October 13, 2016
Pituitary growth hormone (GH) secretion is partially rescued in HIV-infected patients with GH deficiency (GHD) compared to hypopituitary patientsChiara Diazzi, Giulia Brigante, Giulia Ferrannini, et al.
European Journal of Heart Failure|July 7, 2023
Real-world use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure RegistryDavide Stolfo, Lars H Lund, Lina Benson, et al.
Journal of Cardiac Failure|May 13, 2022
Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure PopulationTonje Thorvaldsen, Giulia Ferrannini, Linda Mellbin, et al.
Diabetes Care|December 6, 2023
High Mannose Correlates With Surrogate Indexes of Insulin Resistance and Is Associated With an Increased Risk of Cardiovascular Events Independently of Glycemic Status and Traditional Risk FactorsElena Fortin, Beatrice Campi, Ele Ferrannini, et al.
Cardiovascular Diabetology|July 8, 2022
Mannose-binding lectin does not explain the dismal prognosis after an acute coronary event in dysglycaemic patients. A report from the GAMI cohortSara Meziani, Giulia Ferrannini, Mette Bjerre, et al.
Heart (British Cardiac Society)|May 4, 2026
Defibrillation of persistent shockable rhythms and survival after in-hospital cardiac arrestDavid Brooke Sidebottom, Martin Jonsson, Emma Blick Nordkvist, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
European Journal of Preventive Cardiology|February 24, 2021
Gender gap in risk factor control of coronary patients far from closing: results from the European Society of Cardiology EUROASPIRE V registryPieter Vynckier, Giulia Ferrannini, Lars Rydén, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|August 13, 2022
Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registry analysisGiulia Ferrannini, Lars H Lund, Lina Benson, et al.
Cardiovascular Diabetology|August 11, 2023
Empagliflozin improves insulin sensitivity in patients with recent acute coronary syndrome and newly detected dysglycaemia : Experiences from the randomized, controlled SOCOGAMI trialElena Fortin, Magnus Lundin, Linda Mellbin, et al.
The Lancet. Diabetes & Endocrinology|September 26, 2024
Dysglycaemia screening and its prognostic impact in patients with coronary artery disease: experiences from the EUROASPIRE IV and V cohort studiesGiulia Ferrannini, Jaakko Tuomilehto, Guy De Backer, et al.
Endocrine|October 13, 2016
Pituitary growth hormone (GH) secretion is partially rescued in HIV-infected patients with GH deficiency (GHD) compared to hypopituitary patientsChiara Diazzi, Giulia Brigante, Giulia Ferrannini, et al.
European Journal of Heart Failure|July 7, 2023
Real-world use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure RegistryDavide Stolfo, Lars H Lund, Lina Benson, et al.
Journal of Cardiac Failure|May 13, 2022
Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure PopulationTonje Thorvaldsen, Giulia Ferrannini, Linda Mellbin, et al.
Diabetes Care|December 6, 2023
High Mannose Correlates With Surrogate Indexes of Insulin Resistance and Is Associated With an Increased Risk of Cardiovascular Events Independently of Glycemic Status and Traditional Risk FactorsElena Fortin, Beatrice Campi, Ele Ferrannini, et al.
Cardiovascular Diabetology|July 8, 2022
Mannose-binding lectin does not explain the dismal prognosis after an acute coronary event in dysglycaemic patients. A report from the GAMI cohortSara Meziani, Giulia Ferrannini, Mette Bjerre, et al.
Heart (British Cardiac Society)|May 4, 2026
Defibrillation of persistent shockable rhythms and survival after in-hospital cardiac arrestDavid Brooke Sidebottom, Martin Jonsson, Emma Blick Nordkvist, et al.
Pageof 5